Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

NCT01709435 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

NIH

Sponsor class

Conditions

Recurrent Malignant Solid Neoplasm
Recurrent Melanoma
Recurrent Primary Central Nervous System Neoplasm
Recurrent Thyroid Gland Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Primary Central Nervous System Neoplasm
Thyroid Gland Medullary Carcinoma

Interventions

DRUG: Cabozantinib S-malate
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)